Gastric Cancer - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Gastric Cancer Emerging Therapy and TPP Insights

Thelansis's "Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Gastric Cancer Overview

Gastric cancer is the fifth most common malignancy and third leading cause of cancer mortality globally, arising predominantly as adenocarcinoma from the gastric mucosa, with Helicobacter pylori infection, dietary carcinogens, tobacco, obesity, and hereditary syndromes including CDH1 germline mutations constituting principal aetiological drivers. Molecular classification encompasses EBV-positive, microsatellite instability-high, chromosomally unstable, and genomically stable subtypes, each carrying distinct therapeutic implications. HER2 amplification occurs in approximately 15-20% of gastric and gastroesophageal junction adenocarcinomas, representing a critical actionable biomarker. Patients present with epigastric pain, dysphagia, early satiety, weight loss, and anaemia, with many diagnosed at advanced stages given insidious onset. Upper endoscopy with biopsy establishes histological diagnosis, while CT staging, PET imaging, and laparoscopic staging address metastatic and peritoneal disease assessment. Comprehensive molecular profiling encompassing HER2, MSI, PD-L1 CPS, and FGFR2 status is mandatory at diagnosis. Perioperative FLOT chemotherapy is the established standard for resectable disease. Advanced HER2-positive gastric cancer is addressed with trastuzumab combined with chemotherapy, with trastuzumab deruxtecan demonstrating transformative second-line efficacy in the DESTINY-Gastric trials. Nivolumab combined with chemotherapy is the established frontline standard for HER2-negative advanced disease with CPS of 5 or above. Zolbetuximab, targeting CLDN18.2, combined with chemotherapy represents a significant newly approved frontline advance for CLDN18.2-positive tumours. MSI-H disease benefits from pembrolizumab immunotherapy. Prognosis remains poor in advanced disease; multidisciplinary tumour board evaluation, nutritional support, and early palliative integration are indispensable to patient-centred care.

Key Highlights

• In Germany, survival-adjusted prevalent Gastric Cancer cases are projected to increase from 120,844 in 2025 to 129,241 by 2035.
• Gastric cancer continues to impose significant clinical burden due to late-stage diagnosis.
• HER2-targeted therapies and immunotherapies are increasingly influencing treatment paradigms.
• Unmet need remains high in advanced and metastatic disease management.

Market Overview

• The Spain Gastric Cancer market is projected to grow from USD 220 million in 2025 to USD 580 million by 2035.
• Growth is supported by expanding biomarker testing and adoption of targeted oncology therapies.
• Pipeline therapies including ADCs and immunotherapy combinations are expected to accelerate market expansion.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp & Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome & Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences (Nanjing), Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.